DGIdb - FLUDARABINE Drug Record

FLUDARABINE chembl:CHEMBL1568 AntineoplasticImmunotherapy

Alternate Names:

FLUDARABINE
2-FLUORO-ARA-A

Drug Info:

Drug Class	antineoplastic agents
Year of Approval	1991
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent

(5 More Sources)

Publications:

Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA
Weston et al., 2010, The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo., Blood
Doğan et al., 2004, Effect of fludarabine on leukocyte functions., Chemotherapy
Lech-Maranda et al., 2009, Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity., Mini Rev Med Chem
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Robak et al., 2009, Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases., Molecules
Bosanquet et al., 2002, Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia., Leukemia
Robak et al., 2006, Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity., Curr. Med. Chem.
Barragán et al., 2002, Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells., Blood
Iacobucci I et al., 2013, Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin., Pharmacogenomics J
Jordheim et al., 2005, [Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues]., Bull Cancer
Yao et al., 2010, [Correlation of deoxycytidine kinase gene expression with fludarabine resistance in patients with chronic lymphocytic leukemia]., Zhongguo Shi Yan Xue Ye Xue Za Zhi
Zhang et al., 2006, The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation., Acta Crystallogr. D Biol. Crystallogr.
Maggio et al., 2004, The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells., Cancer Res.
Lepist EI et al., 2013, Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1., Drug Metab Dispos
Younes et al., 1998, Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia., Br. J. Haematol.
Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol

FLUDARABINE POLA1

Interaction Score: 3.25

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name fludarabine phosphate,Fludara

Novel drug target Established target

PMIDs:
19519505 17168705 17016423 17139284 19325518

Sources:
TdgClinicalTrial TEND
FLUDARABINE SULT2B1

Interaction Score: 2.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
FLUDARABINE RRM1

Interaction Score: 1.39

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name fludarabine phosphate,Fludara

Novel drug target Established target

PMIDs:
19519505 17016423 17139284 19325518

Sources:
TdgClinicalTrial TEND
FLUDARABINE DCK

Interaction Score: 1.18

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name fludarabine phosphate,Fludara

Novel drug target Established target

PMIDs:
15820918 20137114 16421443

Sources:
TdgClinicalTrial
FLUDARABINE IKZF1

Interaction Score: 1.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30044693

Sources:
CIViC
FLUDARABINE SLC22A12

Interaction Score: 0.93

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
FLUDARABINE CXCL12

Interaction Score: 0.93

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27173875

Sources:
PharmGKB
FLUDARABINE CD40

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9450802

Sources:
NCI
FLUDARABINE SLC29A1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23388705

Sources:
DTC
FLUDARABINE MPO

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15608444

Sources:
NCI
FLUDARABINE XIAP

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15059916

Sources:
NCI
FLUDARABINE ADA

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
FLUDARABINE CYP2E1

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
FLUDARABINE BAX

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12040435

Sources:
NCI
FLUDARABINE SLCO1B1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
FLUDARABINE ATM

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
20739657

Sources:
JAX-CKB
FLUDARABINE PIK3CG

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11929788

Sources:
NCI
FLUDARABINE SMAD3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FLUDARABINE NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: FLUDARABINE
- Version: 01-August-2011
Alternate Names:

FLUDARABINE Primary Drug Name

Drug Info:

Year of Approval 1991

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: FLUDARABINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: FLUDARABINE

Version: 14-September-2017

Alternate Names:

C1094 NCI drug code

Drug Info:

Publications:

Maggio et al., 2004, The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells., Cancer Res.

Younes et al., 1998, Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia., Br. J. Haematol.

Barragán et al., 2002, Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells., Blood

DTC: FLUDARABINE

Version: 02-September-2020

Alternate Names:

CHEMBL1568 ChEMBL Drug ID

Drug Info:

Publications:

Lepist EI et al., 2013, Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1., Drug Metab Dispos

JAX-CKB: Fludarabine
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Weston et al., 2010, The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo., Blood

PharmGKB: fludarabine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA

Iacobucci I et al., 2013, Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin., Pharmacogenomics J

CIViC: FLUDARABINE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol

TTD: Fludarabine
- Version: 2020.06.01
Alternate Names:

D0F2XQ TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1568
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	fludarabine phosphate,Fludara
Novel drug target	Established target

Evidence Type	Actionable
Approval Status	Preclinical - Cell culture
Response Type	sensitive

FLUDARABINE Drug Record

FLUDARABINE chembl:CHEMBL1568 AntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name fludarabine phosphate,Fludara Novel drug target Established target

PMIDs: 19519505 17168705 17016423 17139284 19325518

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22584460

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name fludarabine phosphate,Fludara Novel drug target Established target

PMIDs: 19519505 17016423 17139284 19325518

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name fludarabine phosphate,Fludara Novel drug target Established target

PMIDs: 15820918 20137114 16421443

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30044693

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22584460

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27173875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9450802

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23388705

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15608444

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15059916

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22584460

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12040435

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22584460

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell culture Response Type sensitive

PMIDs: 20739657

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11929788

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name fludarabine phosphate,Fludara

Novel drug target Established target

PMIDs:
19519505 17168705 17016423 17139284 19325518

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
22584460

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name fludarabine phosphate,Fludara

Novel drug target Established target

PMIDs:
19519505 17016423 17139284 19325518

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name fludarabine phosphate,Fludara

Novel drug target Established target

PMIDs:
15820918 20137114 16421443

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
30044693

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
22584460

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27173875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9450802

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23388705

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
15608444

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15059916

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
22584460

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12040435

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22584460

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
20739657

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
11929788

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

FLUDARABINE Primary Drug Name

Drug Info:

Year of Approval 1991

Drug Class antineoplastic agents

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C1094 NCI drug code

Alternate Names:

CHEMBL1568 ChEMBL Drug ID

Publications:

Lepist EI et al., 2013, Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1., Drug Metab Dispos

Publications:

Weston et al., 2010, The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo., Blood

Publications:

Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol

Alternate Names:

D0F2XQ TTD Drug ID